Skip to main content

Install RediHealth

Add RediHealth to your device for quick access.

  1. Click the install button in the address bar or open the browser menu.
  2. Select install RediHealth and confirm to open it in its own window.

3 min read, 3 min audio

Lecanemab for early-stage Alzheimer's disease

Lecanemab is an antibody medicine given by infusion that targets amyloid, a protein that builds up in the brain in Alzheimer's disease. It is intended for people in the early stages and may modestly slow the decline in memory and thinking. It does not cure the disease and carries notable risks, so careful assessment is required.

Key takeaway: Lecanemab is an antibody medicine given by infusion that targets amyloid, a protein that builds up in the brain in Alzheimer's disease. It is intended for people in the early stages and may modestly slow the decline in memory and thinking. It does not cure the disease and carries notable risks, so careful assessment is required.

Editorial draft: independent clinical and language review is pending. This information cannot diagnose symptoms or replace individual medical advice.

On this page

How it works

In Alzheimer's disease, clumps of amyloid protein form plaques between nerve cells. Lecanemab attaches to amyloid and helps the immune system clear it from the brain. Researchers think reducing amyloid may slow disease progression, although exactly how much this translates into everyday benefit is debated.

Who may be considered

The medicine is intended for people with mild cognitive impairment or mild dementia due to Alzheimer's disease in whom amyloid has been confirmed by a brain scan or spinal fluid test. People with certain risk factors, such as bleeding in the brain, use of blood thinners or genetic features that raise the chance of side effects, may not be suitable. Availability and approval differ between countries.

What studies found

In a large trial lasting eighteen months, people receiving lecanemab declined somewhat more slowly on a rating scale than people receiving placebo. The difference was small, and experts disagree about whether it is noticeable in daily life. Longer-term benefits are still being studied.

Risks and monitoring

Treatment is given as an infusion every two weeks, and brain scans are needed before and during treatment. A known side effect is swelling or small bleeds in the brain, called amyloid-related imaging abnormalities. Most are without symptoms, but some cause headache, confusion or dizziness, and rarely they can be serious. People who carry two copies of a gene variant called APOE4 are at higher risk. Infusion reactions such as fever or chills may also occur.

Making a decision

The decision involves weighing a modest possible slowing of decline against regular infusions, scans, risks and burden on the family. Talk with a specialist about your goals. Support, medicines for symptoms, activity, social contact and care planning remain important with or without this treatment.

Practical examples

These hypothetical situations illustrate decisions and questions. They do not predict a diagnosis or treatment result.

Preparing for a specialist visit

Imagine you have been diagnosed with early Alzheimer's. You could write down questions about whether you qualify, what the benefits are in everyday life and what the monitoring involves, and bring a relative along.

Weighing the burden

Suppose you live far from the hospital. You might discuss how often travel would be needed for infusions and scans and whether this fits with your daily life.

Questions to ask your healthcare team

  • Am I a suitable candidate, and what tests are needed?
  • What realistic benefit and risks should I expect?
  • What other support is available if I decide not to take it?

Questions about your health?

Talk to a volunteer doctor in a voice call. It is free and confidential.

Talk to a doctor

Don't need a doctor?

A pharmacist can advise you for free, without an appointment.

Nearest pharmacy

This guide does not replace a doctor. This page gives you health information. It does not give you a diagnosis or treatment. For that, see a doctor. In an emergency, call 112.

Sources and further reading

Original RediHealth educational article. The examples are hypothetical. This is not a reproduction of an IQWiG article or an endorsement by IQWiG.

The source material is in English. Information about German healthcare services may not apply in other countries.